Glucosamine, Chondroitin, and Joint Supplements: Benefits, Forms, Dosing, and Side Effects

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• References

Overview

Joint supplements are among the most widely used dietary supplements worldwide, with glucosamine and chondroitin alone taken by millions of adults for osteoarthritis and general joint health. Osteoarthritis — the progressive deterioration of cartilage between joint bones — affects over 32 million adults in the United States alone, and the promise of slowing this process without the side effects of long-term NSAID use drives much of the supplement market [1].

The most common joint supplement ingredients include glucosamine, chondroitin sulfate, MSM (methylsulfonylmethane), boswellia extract, collagen, hyaluronic acid, and turmeric/curcumin. Each has a distinct mechanism of action, level of evidence, and appropriate clinical context. The evidence is mixed overall: some ingredients show modest benefits for specific conditions (e.g., chondroitin for hand osteoarthritis, boswellia for knee pain), while others have failed to outperform placebo in well-designed trials [1][2][3].

Glucosamine is thought to promote the formation and repair of cartilage. Chondroitin is believed to promote water retention and elasticity in cartilage and inhibit enzymes that break down cartilage. One emerging mechanism suggests that glucosamine and chondroitin may work partly by altering the gut microbiome toward bacteria that produce short-chain fatty acids such as butyrate, which acts as an anti-inflammatory agent. This was demonstrated in a small placebo-controlled study of 10 subjects taking glucosamine hydrochloride (1,500 mg) and chondroitin sulfate (1,200 mg) daily for two weeks [65].

This article synthesizes the clinical evidence for each major joint supplement ingredient, covering forms, bioavailability, dosing, safety, and drug interactions.

Key terminology:

• WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index): A standardized questionnaire measuring pain, stiffness, and physical function in osteoarthritis. Scores range from 0 to 96 (higher = worse).
• VAS (Visual Analog Scale): A pain measurement tool where patients mark pain intensity on a 0-100 scale.
• Joint space narrowing (JSN): Measured on X-ray, JSN indicates cartilage loss and disease progression. Smaller narrowing over time indicates slower disease progression.
• SYSADOA (Symptomatic Slow-Acting Drugs for Osteoarthritis): A European classification for supplements like chondroitin that may provide gradual symptom relief.

Forms and Bioavailability

Glucosamine

Glucosamine occurs naturally in the body and is a building block for glycosaminoglycans, key structural components of cartilage. Supplemental glucosamine is typically derived from the shells of shrimp or crabs, though a corn-derived (non-shellfish) source is also available [1].

Chemical forms:

Form	Free Glucosamine per 1,500 mg	Notes
Glucosamine hydrochloride (HCl)	1,246 mg	Highest free glucosamine content per gram. Used in the NIH-funded GAIT study. Most common in combination products with chondroitin [1].
Glucosamine sulfate 2-KCl	888 mg	Potassium chloride salt. Used in most European studies where glucosamine alone showed benefit. Considered the preferred sulfate form [1].
Glucosamine sulfate 2-NaCl	938 mg	Sodium chloride salt. Contains additional sodium — may be a concern for those on sodium-restricted diets [1].
N-acetyl-glucosamine (NAG)	Variable	A distinct form used primarily for inflammatory bowel disease and joint collagen production. Not interchangeable with standard glucosamine [1].

There is no conclusive evidence that one glucosamine form is superior to another. However, most positive studies of glucosamine alone (particularly for slowing cartilage loss) have used glucosamine sulfate, while glucosamine hydrochloride has been used more often in combination products with chondroitin [1]. The LEGS study in Australia, which found reduced joint space narrowing with the glucosamine-chondroitin combination, used glucosamine sulfate [1]. If a label states only "glucosamine sulfate" without specifying the salt, it could be either form. People watching their salt intake should look specifically for products stating glucosamine sulfate 2-KCl [1].

Chondroitin Sulfate

Chondroitin sulfate is a sulfated glycosaminoglycan composed of repeating disaccharide units of glucuronic acid and N-acetyl-galactosamine. It is a major structural component of articular cartilage, where it provides resilience and resistance to compression by attracting and retaining water — up to 30 times its own weight [3][4].

Sources:

• Bovine trachea — most common traditional source (up to 3-4% chondroitin sulfate by weight)
• Porcine cartilage — widely used, particularly in pharmaceutical-grade European products
• Shark cartilage — marine source
• Chicken cartilage — avian source
• Vegan/fermented — Mythocondro (produced by fermentation of E. coli, with sulfate chemically added) and algae-derived chondroitin-like mucopolysaccharides [1][3]

Bioavailability: Oral bioavailability ranges from 10-20%, with peak plasma concentrations at 2-4 hours post-dose. Approximately 10% of absorbed chondroitin remains intact, while 90% circulates as depolymerized derivatives. Steady-state concentrations in cartilage are reached after 3-4 days of repeated dosing. The elimination half-life is approximately 4.7-5.2 hours, though some metabolites may persist for up to 15 hours [3].

Purity matters: Chondroitin sulfate purity ranges from about 80% to 95%. The GAIT study used 95%-pure chondroitin sulfate from Bioberica. Pharmaceutical-grade products (e.g., Chondrosulf by IBSA) used in European trials are also typically 95% pure. Lower-purity products may contain contaminants including dermatan sulfate and keratan sulfate, which can affect efficacy [1][3]. FDA testing has found supplement potency ranging from 0% to 115% of labeled amounts, with some market analyses suggesting up to 50% of products have significant quality issues [3].

Molecular weight: Ranges from 14-70 kDa depending on source and processing. Laboratory studies suggest shorter-chain molecules may be better absorbed, though longer chains may be digested to shorter units in the gut. The clinical significance of molecular weight differences is not well established [1][3].

Label reading: Chondroitin is typically sold as chondroitin sulfate, often in a sodium salt form. Labels may state "sodium chondroitin sulfate" or "chondroitin sulfate sodium" — these are complete chemical names and the active ingredient is the same. Labels listing "1,200 mg of chondroitin sulfate (as sodium chondroitin sulfate)" provide 1,200 mg of chondroitin sulfate. Labels listing "1,200 mg of sodium chondroitin sulfate" provide approximately 1,140 mg of chondroitin sulfate, as the sodium contributes about 5% of the total weight [1].

MSM (Methylsulfonylmethane)

MSM occurs naturally in the body but is produced synthetically for supplements. It contributes sulfur to the body, which is used to synthesize certain amino acids and proteins. MSM also acts as an antioxidant. High-quality MSM is an odorless white crystalline powder; improperly manufactured MSM can be contaminated with DMSO, detectable by a faint sulfur or garlic smell [1].

Boswellia (Indian Frankincense)

Boswellia serrata gum resin contains boswellic acids with anti-inflammatory properties. The most potent component is AKBA (3-O-acetyl-11-keto-beta-boswellic acid), a potent inhibitor of 5-lipoxygenase (5-LOX), a key enzyme in leukotriene biosynthesis. Boswellia extracts also inhibit matrix metalloproteinases (MMP-3s), enzymes that break down cartilage, collagen, and connective tissues [1][66][7].

Key standardized extracts:

Extract	AKBA Content	Manufacturer	Notes
5-Loxin	30% AKBA	Sabinsa	High AKBA concentration. Note: "5-Loxin Advanced" is only 20% AKBA despite its name [1]
AprèsFlex / Aflapin	20% AKBA	PLT Health / Laila Nutraceuticals	Enriched with non-volatile resin oils for enhanced absorption [1]
Boswellin	Variable	Sabinsa	Contains total boswellic acids including AKBA [1]
Boswellin Super	30% AKBA	Sabinsa	Standardized to 30% AKBA plus 7.5% beta-boswellic acid, 3.5% 3-O-acetyl-beta-boswellic acid, 1.5% 11-keto-beta-boswellic acid [1]

Boswellia resin should contain at least 1% boswellic acids, while extracts are expected to contain at least 6% [1].

Absorption: Boswellic acids including AKBA are fat-soluble and poorly absorbed with water alone. Absorption may double or more when taken with a fatty meal [5][6]. Formulations containing oils (such as Aflapin) or using liposomes/phytosomes may also enhance absorption [7][8]. Piperine (black pepper extract, sold as Bioperine) is sometimes added to supplements claiming enhanced boswellic acid absorption, but no published studies demonstrate this effect [1].

Collagen

Collagen supplements for joint health typically contain type II collagen, the most abundant collagen in cartilage. Two main forms exist:

• Undenatured (native) type II collagen (e.g., UC-II, NT2): Taken at 40 mg/day (providing ~10 mg collagen) on an empty stomach. Works via oral tolerance — a mechanism where small amounts of intact collagen train the immune system to reduce autoimmune-mediated cartilage destruction [1].
• Hydrolyzed collagen (collagen peptides): Broken down into smaller peptides for absorption. Used at higher doses (typically 5-12.5 g/day). Provides amino acids (glycine, proline, hydroxyproline) as building blocks for collagen synthesis [1].

Collagen supplementation for at least three to six months may, at best, modestly reduce joint stiffness and/or pain according to several preliminary studies using various forms including undenatured collagen, hydrolyzed collagen, and eggshell membrane hydrolysates. Some studies have shown no benefit [1].

Hyaluronic Acid

Hyaluronic acid is a natural component of cartilage and synovial fluid (the fluid around joints). Approximately 1 in 7 people with newly diagnosed knee osteoarthritis in the U.S. are prescribed hyaluronic acid injections [69]. However, a meta-analysis of 169 clinical trials involving more than 21,000 people showed that hyaluronic acid injections do not reduce pain or improve knee function by clinically meaningful amounts, and increased the risk of serious adverse events (hospitalization, disability, life-threatening events, or death) by about 50% compared to placebo [9].

Oral hyaluronic acid is also sometimes used for joint health, but evidence is mixed. Effective doses in clinical studies range from 80-200 mg/day [1]. Supplements are extracted from roosters' combs or produced from bacteria [1].

Turmeric / Curcumin

Curcuminoids and other compounds in turmeric provide an anti-inflammatory effect that may provide modest benefit in rheumatoid arthritis and osteoarthritis, although no better than anti-inflammatory medicines. The typical daily dose ranges from 500 to 2,000 mg of curcuminoids from turmeric extracts. Products that have shown benefit are typically formulated for enhanced absorption, as curcuminoids are otherwise not well absorbed unless taken with a meal containing fats [1].

Evidence for Benefits

Knee Osteoarthritis — Glucosamine and Chondroitin

The GAIT Study (NIH-Funded)

The Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) was a landmark double-blind, randomized, placebo-controlled multicenter trial that enrolled 1,583 patients with knee osteoarthritis. Participants received glucosamine hydrochloride (1,500 mg/day), chondroitin sulfate (1,200 mg/day), the combination, celecoxib (200 mg/day), or placebo for 24 weeks [2].

Key findings:

• Overall, neither glucosamine alone, chondroitin alone, nor the combination significantly reduced pain compared to placebo in the intent-to-treat population (combination response rate: 65.4% vs. placebo: 60.1%, P=0.30)
• In a predefined subgroup of 572 participants with moderate-to-severe baseline pain (WOMAC pain score ≥400 out of 1,000), the combination achieved a clinically meaningful response (≥20% pain reduction) in 79.2% versus 54.3% for placebo (P=0.002)
• The combination did not reduce X-ray joint space narrowing [2]
• Follow-up data through 2010 confirmed sustained symptomatic benefits in the moderate-to-severe pain subgroup [3]

Limitation: The study used glucosamine hydrochloride, not glucosamine sulfate, which may explain the overall null result, as most positive single-ingredient glucosamine studies used the sulfate form [1].

The LEGS Study (Australia)

The Long-term Evaluation of Glucosamine Sulfate (LEGS) study used glucosamine sulfate (1,500 mg/day) and chondroitin sulfate (800 mg/day), focusing primarily on patients with early disease and mild pain [1].

Key findings:

• All groups receiving glucosamine and/or chondroitin reported pain reduction, but the reduction was not significantly greater than placebo
• The combination of glucosamine and chondroitin reduced joint space narrowing to half the amount seen in the placebo group — a statistically significant finding
• Neither glucosamine nor chondroitin alone significantly reduced joint space narrowing
• The combination appeared important, and glucosamine sulfate may be more effective than glucosamine hydrochloride for slowing disease progression [1]

The MOVES Trial

A multicenter, double-blind, randomized non-inferiority trial (n=606) with Kellgren-Lawrence grade II-III knee OA compared pharmaceutical-grade chondroitin sulfate (800 mg/day) plus glucosamine hydrochloride (1,500 mg/day) to celecoxib (200 mg/day) over six months. The combination was non-inferior to celecoxib, with similar reductions in pain (-33.0 vs. -29.5 WOMAC points) and improvements in function. Rescue medication use was lower with the combination (31%) than placebo (48%) [10].

Chondroitin Sulfate vs. Celecoxib

A 6-month European study found that 800 mg of pharmaceutical-grade chondroitin sulfate (95% pure, Chondrosulf, IBSA) was similar to 200 mg of celecoxib in reducing pain and improving function in mild to moderate knee osteoarthritis. On a pain scale of 0-100, pain fell by 42.6 points with chondroitin, 39.6 points with celecoxib, and 33.3 points with placebo. The improvement with chondroitin took longer (6 months vs. 3 months for celecoxib), and all treatments demonstrated excellent safety profiles. The researchers suggested that chondroitin sulfate should be considered a first-line treatment due to its safety advantages over NSAIDs [11].

A 2024 multicenter randomized trial confirmed that 800 mg/day pharmaceutical-grade chondroitin sulfate is non-inferior to celecoxib for reducing pain and improving function over 6 months in symptomatic knee OA [3].

Vegan Chondroitin

A small study among overweight adults (average age 62) with mild to moderate knee osteoarthritis found that 600 mg of non-animal-derived chondroitin sulfate (Mythocondro, produced by fermentation of a specific E. coli strain, with sulfate chemically added) taken once daily for three months modestly improved knee function, mobility, and pain compared to placebo. Certain markers of inflammation (CRP and erythrocyte sedimentation rate) also decreased [12].

Long-term Observational Data

A 6-year study of people with knee osteoarthritis (without total cartilage loss) who reported using glucosamine and chondroitin found no effect on pain reduction but a slight (1%) reduction in cartilage volume loss, particularly in the lateral compartment of the knee [13].

Negative Trials

• A 6-month study of 164 patients with moderate to severe knee OA pain, using 1,500 mg glucosamine sulfate with 1,200 mg chondroitin sulfate daily, failed to demonstrate superiority over placebo in reducing pain or improving function [14].
• A 6-month study of glucosamine hydrochloride (1,500 mg daily as a beverage) in patients with mild to moderate knee pain found it did not decrease pain, reduce worsening of cartilage damage, or improve bone marrow lesions compared to placebo. It also did not decrease urinary markers of cartilage destruction. The authors noted that longer-term studies using glucosamine sulfate, rather than glucosamine hydrochloride, have shown benefit [15].

Cochrane Reviews and Meta-Analyses

A 2015 Cochrane review concluded that chondroitin "may improve pain slightly in the short-term (less than 6 months)" and in 6 out of 100 people it may improve pain by 20%. Additionally, chondroitin "slightly slows down narrowing of the joint space" and people taking it reported fewer adverse effects than those taking placebo [16]. A 2007 review of large-scale studies concluded that chondroitin alone did not provide benefit for knee or hip osteoarthritis [17].

A 2010 Cochrane systematic review of 10 RCTs (~3,800 participants) found low-quality evidence for small but statistically significant pain relief (standardized mean difference -0.18, about 5-6 mm on a 0-100 mm VAS) with chondroitin, though the clinical relevance of this small effect is questionable. Benefits for function and stiffness were inconsistent. There was moderate evidence of a small effect on joint space narrowing (mean difference -0.14 mm). However, high risk of bias was present in many trials, particularly industry-sponsored ones. A 2022 update confirmed no clinically relevant benefits for pain or joint structure in high-quality trials [3].

Meta-analyses through 2020 found that chondroitin (800-1,200 mg/day) slightly reduces joint space narrowing (mean difference 0.07 mm/year) with effects consistent across 6-24 months, but limited by heterogeneity and bias. Meta-analyses report 20-30% improvements in WOMAC pain scores after 6-12 months, outperforming placebo by 6-10 points on a 0-100 scale, with a number needed to treat (NNT) of 5 for meaningful relief [3].

Guideline Positions

The American College of Rheumatology/Arthritis Foundation (2020) advises against glucosamine supplementation for knee, hip, or hand osteoarthritis and against chondroitin for knee and hip osteoarthritis, citing concerns about evidence quality (most positive studies were company-funded; studies with least bias risk found no benefit). However, it noted that one trial suggests benefit with chondroitin sulfate for hand osteoarthritis [18].

The European League Against Rheumatism (EULAR) classified pharmaceutical-grade chondroitin sulfate as a SYSADOA with evidence level 1A [3]. OARSI (2019) gave a conditional recommendation for chondroitin in patients with moderate to severe pain and no comorbidities [3]. The FDA in 2004 denied petitions for qualified health claims linking glucosamine and/or chondroitin to a reduced risk of osteoarthritis [3].

Hand Osteoarthritis

A 6-month study of chondroitin sulfate (800 mg once daily) versus placebo in patients with hand osteoarthritis showed a significantly greater decrease in hand pain and improvement in hand function among those taking chondroitin sulfate. The duration of morning stiffness was also slightly reduced. These benefits were not noticeable until after 3 months of treatment. There was no significant difference in grip strength or analgesic use. The chondroitin tested was 95%-pure, fish-origin Chondrosulf (IBSA) [19].

A separate study found that patients with hand and knee osteoarthritis given 1,500 mg of glucosamine sulfate daily for their knees also showed, after 3 months, significantly greater decrease in hand pain and improvement in hand function compared to patients not receiving glucosamine. The glucosamine group chose to use lower amounts of anti-inflammatory medications. Weaknesses included retrospective design, lack of placebo, and unblinded treatment [20].

Lower Back Pain

A well-controlled study of glucosamine sulfate (1,500 mg/day) versus placebo for lower back pain caused by osteoarthritis found that both groups improved, but there was no significant difference between them, suggesting glucosamine is not effective for lower back pain [21].

Hip Osteoarthritis

The evidence for glucosamine and chondroitin in hip osteoarthritis is weak. The ACR/Arthritis Foundation advises against supplementation for hip OA [18]. The 2007 Cochrane meta-analysis found no benefit for hip osteoarthritis [17].

Boswellia for Knee Osteoarthritis

Multiple studies have demonstrated benefit, though most involve company funding:

Boswellin extract (Sabinsa): A study of 48 patients found that Boswellia extract (87.3 mg total boswellic acids including 53.27 mg AKBA per tablet, taken twice daily) for four months reduced knee pain, stiffness, and improved function versus placebo. X-ray imaging showed significant increase in knee joint space and decrease in bone spurs in the Boswellia group, while placebo showed decreased joint space. No serious adverse events were reported [22].

Boswellin Super (150 mg twice daily): A study of 89 patients with mild to moderate degenerative hypertrophy knee osteoarthritis found significant decreases in self-reported pain (21 points on VAS 0-100) and stiffness (27 points on WOMAC 0-96) versus no decrease in VAS and only 8.9-point decrease in WOMAC for placebo over three months. Walking distance also modestly increased. Forty-two percent of extract users showed improvement in joint spacing and decrease in osteophytes versus 13% of placebo. A higher dose (300 mg twice daily) resulted in similar improvements. Several study authors were Sabinsa employees, though the company did not directly fund the study [23].

AprèsFlex/Aflapin (100 mg daily): A study of 67 adults (average age 51) with mild to moderate knee osteoarthritis found that 50 mg twice daily (100 mg total, providing 20 mg AKBA daily) for one month reduced knee pain, stiffness, and functional limitation by 50%, 65%, and 46%, respectively, versus placebo, as measured by WOMAC. Blood markers of inflammation (TNF-alpha and hsCRP) also modestly decreased. The study was funded by Laila Nutraceuticals [24].

A subsequent 6-month study (n=73, average age 48) by the same research group showed the same dose taken once daily in the morning after breakfast reduced pain, stiffness, and functional limitations by 70%, 72%, and 71% respectively versus baseline (vs. 26%, 16%, and 18% for placebo). Boswellia also increased 6-minute walk distance by 69.1 meters and reduced stair-climbing time by 3.43 seconds versus placebo. Joint spacing and cartilage thickness slightly improved while the placebo group showed significant worsening [25].

Generic Boswellia extract (40% total boswellic acids, 2% AKBA): Given at 333 mg three times daily for 8 weeks, all patients receiving the extract reported decreased knee pain, increased knee flexion, and increased walking distance. Frequency of knee joint swelling also decreased [26].

Boswellia-curcumin combination: Capsules containing 350 mg curcuminoids and 140 mg boswellic acid, taken three times daily, were modestly effective in reducing knee OA pain and slightly more effective than curcumin alone for physical function [27].

Negative trial (hand osteoarthritis): A study of 106 adults (average age 66) with moderate to severe hand osteoarthritis found that a combination of 250 mg Boswellia extract, 100 mg pine bark extract, 1,500 mg MSM, and 168 mg curcumin daily for 12 weeks did not significantly reduce hand pain compared to placebo. Both groups showed significant pain reductions from baseline, indicating a large placebo effect. The supplement also did not reduce work or activity impairment, or improve function or quality of life [28].

Other boswellia uses: Preliminary studies suggest possible benefit in asthma, Crohn's disease, and cancer. Boswellia resin (300-350 mg three times daily for 6 weeks) has been shown to be as effective as, if not more effective than, the drug sulfasalazine for ulcerative colitis symptoms [67][68]. Studies in rheumatoid arthritis have yielded mixed results [1].

MSM for Joint Pain and Other Conditions

The evidence for MSM remains limited:

• A placebo-controlled study of half-marathon competitors found that MSM (3,000 mg/day for 21 days before and 2 days after the race) led to less muscle and joint pain post-race, but the reductions were not statistically significant and MSM did not reduce biological markers of oxidative stress or muscle damage [29].
• A study among 63 women (ages 35-59) found that 1,000 mg or 3,000 mg MSM daily for 4 months improved nail shine and hair shine/volume compared to baseline. However, the study lacked a placebo group, which is needed to prove benefit. The higher dose worked faster (improvements at 4 weeks vs. 8 weeks) [30].
• MSM eye drops marketed for dry eye are not legally marketed in the U.S. A brand was recalled in 2023 for bacterial and fungal contamination [1].

N-Acetyl-Glucosamine (NAG)

Inflammatory Bowel Disease

NAG is naturally produced in the body and helps maintain and repair the mucus lining of the gastrointestinal tract. In Crohn's disease and ulcerative colitis, the body's ability to produce NAG may be reduced [31].

• A study in children with severe treatment-resistant Crohn's or ulcerative colitis found 8 of 12 children receiving NAG powder (3-6 g/day in three divided doses) had clinical improvement; 4 had no improvement and required surgery [32].
• Adults with IBD given 6 g/day of NAG powder in three divided doses reported improvements in abdominal pain (58.8% of patients, average symptom score decreased 49%), diarrhea (64.7%, score decreased 47%), and nausea (41.2%, score decreased 55%) [33].
• Health Canada allows the claim "Helps promote a healthy intestinal lining in people with symptoms associated with inflammatory bowel disease" for products providing 3,000 mg NAG and 600 mg vitamin C daily [1].
• No published clinical studies exist for NAG and irritable bowel syndrome (IBS), though one is underway (NCT02504060) [1].

Joint Health

• A placebo-controlled study found that 500 mg NAG daily slowed the breakdown and increased the production of type II collagen in healthy adults (average age 48) without arthritis [34].
• A study of older adults in Japan with knee pain and stiffness found that NAG (100 mg) plus chondroitin sulfate (180 mg) daily for five months modestly improved function during household activities but did not improve leisure-time physical activity or reduce pain versus placebo [35].

Hyaluronic Acid — Oral Supplementation

Injections — negative meta-analysis: Despite widespread clinical use, a meta-analysis of 169 trials (n > 21,000) found that hyaluronic acid injections do not reduce pain or improve function by clinically meaningful amounts and increased serious adverse events by ~50% versus placebo [9].

Oral supplementation — mixed evidence:

• Two studies of branded hyaluronic acid (Hyabest, Kewpie Co.) suggest that 200 mg/day for up to two months may improve pain and stiffness in people with severe knee OA pain but appears no more effective than placebo for mild to moderate pain or when taken for longer periods [36][37].
• A study of 31 healthy adults with knee pain (without OA) found that 111 mg/day for 12 weeks did not significantly improve physical function (ability to stand or balance on one leg) but seemed to lessen self-reported knee pain, stiffness, and discomfort (e.g., descending stairs, walking long distances) versus placebo [38].
• A formula combining hyaluronic acid and collagen (Hyal-Joint, Bioiberica) failed to show benefit versus placebo in knee OA [39].
• However, 80 mg/day of hyaluronic acid (Oralvisc, Bioiberica) for 3 months significantly reduced pain, stiffness, and blood markers of inflammation in overweight/obese people with knee OA versus placebo. Those taking hyaluronic acid also had a significant decrease in leptin levels (a hormone elevated in obesity) [40].

Practical note: If trying oral hyaluronic acid, use amounts from clinical studies (80-200 mg/day). Many joint supplements add only a few milligrams per serving — well below clinically studied amounts. Some contain proprietary blends with hyaluronic acid where the actual amount cannot be determined [1].

Dr Brad Stanfield's MicroVitamin Capsules include 200 mg of hyaluronic acid — a dose within the clinically studied range for joint and skin support. The MicroVitamin+ Powder includes 200 mg of hyaluronic acid plus 10 g of collagen peptides, combining two joint-supportive ingredients in a single daily scoop.

Cardiovascular Associations

There is mixed observational evidence regarding glucosamine/chondroitin and cardiovascular outcomes. No clinical trials have been conducted — all evidence is from population studies.

Potentially beneficial associations:

• A study of Washington state residents (ages 50-76) found glucosamine and chondroitin use were each associated with 17% lower mortality over 5 years, while no such association was found for 13 different vitamins and minerals, fish oil, fiber, or several herbal supplements. The authors proposed the benefit may relate to anti-inflammatory properties. Further analysis revealed that glucosamine without chondroitin was associated with an even greater (22%) mortality reduction. Glucosamine was also associated with a 41% reduction in respiratory disease mortality [41][42].
• A UK Biobank study (~500,000 adults) found self-reported glucosamine use associated with 15% lower cardiovascular disease risk, 22% lower mortality, 18% lower coronary heart disease risk (37% lower in current smokers), and 9% lower stroke risk over ~7 years. Although dose and type of glucosamine were not collected, glucosamine is a prescription medication in the UK and most products are glucosamine sulfate [43].
• The same UK data found regular glucosamine use associated with 17% lower type 2 diabetes risk, even after adjusting for common risk factors [44].

Potentially harmful associations:

• A large Chinese observational study found glucosamine supplementation associated with a 12% increased risk of coronary heart disease and 10% increased risk of overall cardiovascular disease among people with osteoarthritis. Risk was greatest in those with highest adherence (68% increased risk with high adherence, 26% with partial adherence; no increased risk with low adherence). The analysis did not adjust for OA severity, obesity, or physical activity level [45].

Safety meta-analysis: A 2023 systematic review of RCTs concluded that glucosamine sulfate, chondroitin sulfate, and their combination exhibit a good safety profile with no significant increase in adverse cardiovascular events [3].

Cancer

A study following 20,541 new users of glucosamine and matched non-users for ~8 years found that glucosamine use was not associated with increased or decreased risk of lung, colorectal, breast, or prostate cancer [46]. Some earlier studies had suggested a lower risk of lung cancer and colorectal cancer among glucosamine users, but these studies may have been skewed by "survivor bias" — including people who had already been taking glucosamine prior to the studies, thereby selecting for individuals who may have "survived" potential negative effects [47].

Additionally, chondroitin sulfate is a component of versican, a substance that appears to support the spread of prostate cancer. However, chondroitin sulfate itself has not been shown to promote cancer [58][59].

Depression

Glucosamine does not appear to have an antidepressant effect. A study of 20 people with major depression (no placebo control) found only 20% reported symptom reduction — worse than the typical 37% placebo response in depression trials. Glucosamine was given as 1 g daily for one week followed by 2 g daily for 3 weeks [48].

Depression and depressive mood has been reported as a side effect by a small percentage (6% or less) of people taking glucosamine sulfate (1,500 mg daily) for osteoarthritis in clinical trials, but the frequency was not significantly different from placebo groups [49][50].

Exercise as a Complement

A study of 206 adults with knee osteoarthritis found that following a 24-week, self-administered exercise and physical activity program resulted in clinically important pain reductions in 72.1% of participants and function improvements in 68%. The program — developed by physiotherapists at the University of Melbourne and available free at https://mykneeexercise.org.au/ — consists of three phases of exercise (each ~2 months), with demonstrated exercises and weekly motivational messages [51].

Recommended Dosing

Glucosamine

• Standard dose: 1,500 mg/day of glucosamine sulfate or glucosamine hydrochloride
• Divided dosing: Traditionally taken as 500 mg three times daily or 750 mg twice daily
• Single daily dose: 1,500 mg once daily has been used successfully in the LEGS study with glucosamine sulfate [1]

Chondroitin Sulfate

• Standard dose: 800-1,200 mg/day of chondroitin sulfate
• Divided dosing: 400 mg three times daily or 600 mg twice daily
• Single daily dose: 800 mg once daily has shown benefit in hand OA and in the chondroitin vs. celecoxib trial (taken each evening with water) [1][11][19]
• Combination dose: When used with glucosamine, typical doses are 1,500 mg glucosamine + 800-1,200 mg chondroitin daily [1]

Boswellia

• AprèsFlex/Aflapin (20% AKBA): 50 mg twice daily or 100 mg once daily — shown effective within 1 month [24][25]
• 5-Loxin (30% AKBA): 100-250 mg daily, with initial benefit from the higher dose seen within 7 days [7][52]
• Boswellin Super (30% AKBA): 150 mg twice daily [23]
• Generic extract (40% total boswellic acids): 333 mg three times daily (1,000 mg/day) [26]
• Take with a fatty meal to enhance absorption of fat-soluble boswellic acids [5][6]
• The dose is typically divided in half and taken twice daily [1]

MSM

• Typical dose: 2,000 mg/day (2 g)
• Range: 500 mg to 3,000 mg/day, with some recommendations up to 8 g/day
• Few well-controlled studies exist, making optimal dose determination difficult [1]

N-Acetyl-Glucosamine (NAG)

• IBD: 3,000-6,000 mg/day in three divided doses [32][33]
• Joint collagen support: 500 mg/day [34]

Collagen (for Joint Health)

• Undenatured type II collagen (UC-II, NT2): 40 mg/day (providing ~10 mg collagen), taken on an empty stomach at bedtime [1]
• Hydrolyzed collagen peptides: 5,000-12,500 mg/day

Hyaluronic Acid (Oral)

• Dose range: 80-200 mg/day based on clinical studies [1][36][40]
• Duration: At least 2-3 months for potential benefit

Practical Guidance

• Benefits from glucosamine and chondroitin may take several weeks to 3 months to appear [1]
• If no positive response within 3 months, continuing or increasing the dose is not indicated [1]
• Once benefit is established, dose reduction may be possible: those under 200 lbs could try 1,000 mg glucosamine + 800 mg chondroitin; those under 115 lbs could try 500 mg glucosamine + 400 mg chondroitin. Return to full dose if symptoms recur [1]
• Those over 200 lbs should stay on the full dosage [1]
• These supplements are unlikely to help those with severe osteoarthritis where cartilage has completely worn away [1]
• Weight loss and switching from high-impact to low-impact exercise are also strongly advised for osteoarthritis management [1]

How to Read a Supplement Label

The weight of the glucosamine compound and the weight of free glucosamine differ significantly:

• 1,500 mg glucosamine HCl = 1,246 mg free glucosamine
• 1,500 mg glucosamine sulfate 2-KCl = 888 mg free glucosamine
• 1,500 mg glucosamine sulfate 2-NaCl = 938 mg free glucosamine

Despite the hydrochloride form providing more free glucosamine, 1,500 mg/day of either form appears effective [1].

For chondroitin: 1,200 mg of chondroitin sulfate from the sodium salt form will contribute about 60 mg/day of sodium. To reduce sodium intake, consider products with the calcium salt form, which adds about 191 mg of calcium/day instead [1].

Safety and Side Effects

Glucosamine

• Common side effects: Gastrointestinal discomfort, drowsiness, skin reactions, and headache [2]
• Blood sugar: Despite being an amino sugar, human studies have not found evidence of increased blood sugar. One study found 1,500 mg glucosamine sulfate for 3 years slightly lowered fasting blood sugar in older adults with knee OA [49]. A large UK study found glucosamine use associated with decreased diabetes risk [44]
• Shellfish allergy: Glucosamine from shrimp/crab shells may cause reactions in shellfish-allergic individuals. Vegetable-based glucosamine (branded as Regenasure or GreenGrown) is available [1]
• Intraocular pressure (glaucoma risk): In people with open-angle glaucoma or ocular hypertension, eye pressure measurements were ~18% higher while taking glucosamine and returned to pre-supplement levels when discontinued [53]. In people without glaucoma, a 9% increase was observed; clinically significant risk (≥2 mmHg rise) was 2.7 times greater in the glucosamine group, with average age of affected individuals being 66 [54]. However, a Thai study of 88 people without glaucoma found no increase after 6 months of use [55]
• Liver toxicity: Rare case reports in two older women with chronic hepatitis C whose liver enzymes elevated on glucosamine and normalized upon discontinuation. Prudent to discontinue if liver enzyme alterations occur; those with chronic hepatitis C may want to avoid glucosamine [56]

Chondroitin Sulfate

• Common side effects: Occasional stomach upset, generally mild (less than 5% incidence). No significant hematologic effects observed in clinical trials [1][3]
• Bleeding risk: Structurally similar to heparin; may enhance anticoagulant effects. Reports of increased INR and bleeding risk in warfarin users. Notify healthcare providers of dose and changes [1][3]
• Asthma exacerbation: Worsening asthma symptoms reported in a 52-year-old woman taking glucosamine/chondroitin, persisting for three weeks despite increased asthma medication, resolving within 24 hours of stopping supplementation. People with asthma have elevated antibodies to chondroitin sulfate in their airways [57]
• Prostate cancer concern: Chondroitin sulfate is a component of versican, which supports prostate cancer spread, but chondroitin sulfate itself has not been shown to promote cancer [58][59]
• Sodium content: 1,200 mg chondroitin sulfate from sodium salt forms contributes ~60 mg sodium/day. Calcium salt alternatives available [1]
• Manganese in combination products: Some glucosamine-chondroitin products contain manganese exceeding the recommended 2.3 mg/day for men and 1.8 mg/day for women. Prolonged intake above 11 mg/day carries risk of neurological side effects. Acceptable during short-term initial therapy but should not be exceeded long-term [1]
• Pregnancy: Category C — limited safety data; generally recommended to avoid [3]
• Rare liver effects: Transient liver enzyme elevations reported rarely in long-term use, particularly with pre-existing liver conditions [3]

MSM

• Generally safe at recommended doses
• Common side effects: Occasional nausea, diarrhea, or headache [1]
• Aspirin-like effect: Avoid with blood-thinning drugs unless medically supervised [1]
• Not evaluated in children or pregnant/breastfeeding women [1]

Boswellia

• Generally well-tolerated at clinical doses
• Reported side effects: Diarrhea, heartburn, nausea, abdominal pain — generally not severe enough to cause discontinuation. Headache, itching, and foot swelling have also been reported [7]
• Allergic contact dermatitis: One confirmed case of blistering rash from topical application (confirmed by allergen patch test) [60]

Collagen

• Generally well-tolerated
• Mild side effects: GI symptoms, headache, dizziness, rash
• Allergen risk: Avoid products derived from sources to which you are allergic (e.g., fish collagen if fish-allergic) [1]

Hyaluronic Acid (Oral)

• Generally safe when taken as a supplement
• One study participant stopped due to developing a rash
• Injections carry higher risk: Rare anaphylaxis reported; the meta-analysis found ~50% increased serious adverse events versus placebo injections [9]

Turmeric / Curcumin

• Generally safe but GI side effects may occur at higher doses
• Potential problems for people with gallbladder disease, kidney stones, or those taking blood-thinning or blood-sugar-lowering medications
• Rare liver injury reported
• Bioavailability enhancers (e.g., piperine) can potentially affect numerous other drugs [1]

White Willow Bark

Sometimes added to joint health formulas. Contains salicin, a precursor to salicylic acid (the active metabolite of aspirin), acting as both COX-1 and COX-2 inhibitor [61]. Side effects include headache and dizziness [62]. Contraindicated in people sensitive or allergic to salicylates — allergic reactions including rash, itchiness, and asthma have been reported, and in rare cases, anaphylaxis [63][64].

Drug Interactions

Supplement	Interacting Drug	Effect	Recommendation
Glucosamine	Warfarin (Coumadin)	May increase INR and bleeding risk	Monitor INR closely; inform healthcare provider of dose changes [1]
Chondroitin	Warfarin, heparin	Structural similarity to heparin; may potentiate anticoagulant effects	INR monitoring recommended; inform healthcare provider [1][3]
Chondroitin	Aspirin / antiplatelet agents	May amplify bleeding risk	Use with caution [3]
Chondroitin	NSAIDs	May reduce required NSAID dosage; additive GI effects possible	Monitor GI symptoms [3]
MSM	Blood-thinning drugs	Aspirin-like effect	Avoid unless medically supervised [1]
Boswellia	CYP-metabolized drugs	Limited data on interactions	No major interactions established; take with fatty meal for absorption [1]
Turmeric/Curcumin	Blood-thinning drugs	May increase bleeding risk	Use with caution [1]
Turmeric/Curcumin	Blood-sugar-lowering drugs	May enhance hypoglycemic effect	Monitor blood sugar [1]
White willow bark	Aspirin, salicylates	Additive salicylate effects	Contraindicated in salicylate-sensitive individuals [61][62]

General advice: Before starting any joint supplement, consult a physician to confirm your diagnosis. This is particularly important with hip pain, which may be caused by rheumatoid arthritis, infection, damaged blood supply, gout, or other diseases for which treatment with these supplements would be inappropriate [1].

Dietary Sources

Glucosamine

Glucosamine is not typically obtained from food in meaningful supplemental amounts. It is produced endogenously in the body from glucose and the amino acid glutamine. The shells of shrimp, crab, and lobster are the richest natural sources and are the starting material for most glucosamine supplements [1].

Chondroitin Sulfate

Chondroitin sulfate is found naturally in animal cartilage — bovine trachea, porcine cartilage, shark cartilage, and chicken keel cartilage. It is not present in significant quantities in common dietary foods. Bone broth contains small amounts of glycosaminoglycans including chondroitin sulfate, though the amounts are highly variable and unlikely to reach therapeutic doses [3]. Global production is dominated by China, accounting for approximately 80% of the market (over 6,000 tons annually) [3].

Sulfur (Relevant to MSM)

MSM provides sulfur to the body. Dietary sulfur sources include:

• Cruciferous vegetables: Broccoli, Brussels sprouts, cabbage, cauliflower
• Allium vegetables: Garlic, onions, leeks
• Protein-rich foods: Eggs, meat, poultry, fish (contain sulfur-containing amino acids methionine and cysteine)

Boswellic Acids

Not found in common foods. Obtained exclusively from the gum resin of Boswellia serrata (Indian frankincense tree) [1].

Collagen

• Bone broth — contains variable amounts of collagen
• Meat, poultry, fish — contain collagen in connective tissues and skin
• Gelatin — denatured collagen used in cooking
• Amino acid precursors (glycine, proline, vitamin C) support endogenous collagen production

Hyaluronic Acid

• Bone broth — contains hyaluronic acid from connective tissues
• Root vegetables — small amounts
• Endogenous production is supported by adequate vitamin C, magnesium, and zinc
• Supplements are extracted from roosters' combs or produced from bacteria [1]

References

1. ConsumerLab. "Glucosamine, Chondroitin, MSM, and Boswellia Supplements Review." Accessed 2025. https://www.consumerlab.com/reviews/review-glucosamine-chondroitin-msm-boswellia-supplements/jointsupplements/

2. Clegg DO, Reda DJ, Harris CL, et al. "Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis." N Engl J Med. 2006;354(8):795-808. doi: 10.1056/NEJMoa052771

3. Grokipedia. "Chondroitin sulfate." https://grokipedia.com/page/Chondroitin. Data from: Singh JA et al., Cochrane Library 2015; GAIT (Clegg 2006); MOVES (Hochberg 2016); EULAR 2003; OARSI 2019; ACR 2020.

4. Kiani C, Chen L, Wu YJ, Yee AJ, Yang BB. "Structure and function of aggrecan." Cell Res. 2002;12(1):19-32. doi: 10.1038/sj.cr.7290106

5. Sterk V, Buchele B, Simmet T. "Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers." Planta Med. 2004;70(12):1155-1160. doi: 10.1055/s-2004-835844

6. Skarke C, et al. "Pharmacokinetics of boswellic acids in healthy volunteers." J Clin Pharmacol. 2012;52(10):1546-1559. doi: 10.1177/0091270011422811

7. Sengupta K, Alluri KV, Satish AR, et al. "A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee." Arthritis Res Ther. 2008;10(4):R85. doi: 10.1186/ar2461

8. Husch J, et al. "Enhanced absorption of boswellic acids by a lecithin delivery form (Phytosome) of Boswellia extract." Fitoterapia. 2013;87:89-98. doi: 10.1016/j.fitote.2013.03.007

9. Pereira TV, et al. "Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis." BMJ. 2022;378:e069722. doi: 10.1136/bmj-2022-069722

10. Hochberg MC, Martel-Pelletier J, Monfort J, et al. "Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib." Ann Rheum Dis. 2016;75(1):37-44. doi: 10.1136/annrheumdis-2014-206792

11. Reginster JY, et al. "Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis." Ann Rheum Dis. 2017;76(9):1537-1543. doi: 10.1136/annrheumdis-2016-210860

12. Rondenelli F, et al. "Effects of non-animal derived chondroitin sulfate supplementation on knee osteoarthritis." Nutrients. 2019;11(5):1091. doi: 10.3390/nu11051091

13. Raynauld JP, et al. "Long-term effects of glucosamine and chondroitin sulfate on the progression of structural changes in knee osteoarthritis." Arthritis Care Res (Hoboken). 2016;68(10):1560-1566. doi: 10.1002/acr.22866

14. Herrero-Beaumont G, et al. "Glucosamine sulfate with chondroitin sulfate in patients with knee osteoarthritis." OARSI abstract, Osteoarthritis Cartilage. 2016.

15. Kwoh CK, et al. "Effect of oral glucosamine on joint structure in individuals with chronic knee pain." Arthritis Rheum. 2014;66(4):930-939. doi: 10.1002/art.38314

16. Singh JA, et al. "Chondroitin for osteoarthritis." Cochrane Database Syst Rev. 2015;(1):CD005614. doi: 10.1002/14651858.CD005614.pub2

17. Reichenbach S, et al. "Meta-analysis: chondroitin for osteoarthritis of the knee or hip." Ann Intern Med. 2007;146(8):580-590. doi: 10.7326/0003-4819-146-8-200704170-00009

18. Kolasinski SL, et al. "2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee." Arthritis Rheumatol. 2020;72(2):220-233. doi: 10.1002/art.41142

19. Gabay C, et al. "Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis." Arthritis Rheum. 2011;63(11):3383-3391. doi: 10.1002/art.30574

20. Tenti S, et al. "Effects of glucosamine sulfate supplementation on hand osteoarthritis in patients treated for knee osteoarthritis." Aging Clin Exp Res. 2019;31(11):1613-1619. doi: 10.1007/s40520-019-01151-0

21. Wilkens P, et al. "Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis." JAMA. 2010;304(1):45-52. doi: 10.1001/jama.2010.893

22. Majeed M, et al. "A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee." Phytother Res. 2019;33(5):1457-1468. doi: 10.1002/ptr.6338

23. Majeed M, et al. "Efficacy of Boswellin Super in the Management of Degenerative Hypertrophy Osteoarthritis of the Knee." Front Pharmacol. 2024;15:1349189. doi: 10.3389/fphar.2024.1349189

24. Karlapudi V, et al. "A Placebo-Controlled Double-Blind Study Demonstrates the Clinical Efficacy of a Novel Herbal Formulation for Relieving Joint Discomfort in Human Subjects with Osteoarthritis of Knee." J Am Nutr Assoc. 2023;42(4):396-406. doi: 10.1080/07315724.2022.2053418

25. Kumar D, et al. "Evaluation of the Efficacy of AprèsFlex in the Management of Osteoarthritis of Knee." J Am Nutr Assoc. 2024. doi: 10.1080/27697061.2024.2316135

26. Kimmatkar N, et al. "Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee." Phytomedicine. 2003;10(1):3-7. doi: 10.1078/094471103321648593

27. Haroyan A, et al. "Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study." BMC Complement Altern Med. 2018;18(1):7. doi: 10.1186/s12906-017-2062-z

28. Liu Y, et al. "Effect of a Combination Botanical Supplement on Hand Osteoarthritis Pain." Arthritis Rheumatol. 2024;76(Suppl 9). doi: 10.1002/art.42993

29. Withee ED, et al. "Effects of Methylsulfonylmethane (MSM) on exercise-induced oxidative stress, muscle damage, and pain following a half-marathon." J Int Soc Sports Nutr. 2017;14:24. doi: 10.1186/s12970-017-0181-z

30. Muizzuddin N, et al. "Effect of MSM supplementation on hair and nail health." Nat Med J. 2019.

31. Goodman MJ, et al. "N-acetylglucosamine and the mucus barrier." Gut. 1997;40(5):687-688. doi: 10.1136/gut.40.5.687

32. Salvatore S, et al. "A pilot study of N-acetyl glucosamine, a nutritional substrate for glycosaminoglycan synthesis, in paediatric chronic inflammatory bowel disease." Aliment Pharmacol Ther. 2000;14(12):1567-1579. doi: 10.1046/j.1365-2036.2000.00883.x

33. Zhu M, et al. "N-Acetyl Glucosamine for Treatment of Inflammatory Bowel Disease." Nat Med J. 2015.

34. Tomonaga A, et al. "N-Acetyl Glucosamine Stimulates the Production of Type II Collagen in Healthy Adults." Exp Ther Med. 2016;12(6):4029-4033. doi: 10.3892/etm.2016.3869

35. Tsuji T, et al. "Efficacy and safety of glucosamine and chondroitin in older Japanese adults with knee pain." Aging Clin Exp Res. 2016;28(2):197-205. doi: 10.1007/s40520-015-0414-7

36. Sato T, et al. "Clinical effects of hyaluronic acid diet for dry skin and wrinkle." J New Rem Clin. 2009.

37. Tashiro T, et al. "Oral administration of polymer hyaluronic acid alleviates symptoms of knee osteoarthritis." Sci World J. 2012;2012:167928. doi: 10.1100/2012/167928

38. Sugiyama M, et al. "Effects of oral hyaluronic acid on knee function in healthy adults with knee discomfort." Exp Ther Med. 2023;26(3):463. doi: 10.3892/etm.2023.12162

39. Kalman DS, et al. "Effect of a natural extract of chicken combs with a high content of hyaluronic acid (Hyal-Joint) on pain relief and quality of life in subjects with knee osteoarthritis." Nutr J. 2008;7:3. doi: 10.1186/1475-2891-7-3

40. Nelson FR, et al. "The effects of an oral preparation containing hyaluronic acid (Oralvisc) on obese knee osteoarthritis patients." Rheumatol Int. 2015;35(1):43-52. doi: 10.1007/s00296-014-3077-2

41. Pocobelli G, et al. "Use of supplements of multivitamins, vitamin C, and vitamin E in relation to mortality." Am J Clin Nutr. 2010;91(1):255. doi: 10.3945/ajcn.2009.28129

42. Bell GA, et al. "Use of glucosamine and chondroitin in relation to mortality." Eur J Epidemiol. 2012;27(8):593-603. doi: 10.1007/s10654-012-9714-6

43. Ma H, et al. "Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank." BMJ. 2019;365:l1628. doi: 10.1136/bmj.l1628

44. Ma H, et al. "Habitual glucosamine use, risk of incident type 2 diabetes, and related metabolic traits." Diabetes Care. 2020;43(9):e116-e118.

45. Yu D, et al. "Association of Glucosamine Supplementation With Cardiovascular Disease in Chinese Adults With Osteoarthritis." Nutrients. 2022;14(5):1020. doi: 10.3390/nu14051020

46. Suissa S, et al. "Glucosamine use and risk of lung, colorectal, breast, and prostate cancer." Arthritis Care Res (Hoboken). 2024;76(1):96-104. doi: 10.1002/acr.25241

47. Suissa S, et al. "Glucosamine and cancer: survivor bias in observational studies." Pharmacoepidemiol Drug Saf. 2022;31(10):1059-1062. doi: 10.1002/pds.5526

48. Kumar A, et al. "Clinical efficacy of glucosamine sulfate in major depressive disorder." Asian J Psychiatry. 2020;47:101878. doi: 10.1016/j.ajp.2019.101878

49. Reginster JY, et al. "Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial." Lancet. 2001;357(9252):251-256. doi: 10.1016/S0140-6736(00)03610-2

50. Hughes R, et al. "A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee." Rheumatology. 2002;41(3):279-284. doi: 10.1093/rheumatology/41.3.279

51. Nelligan RK, et al. "Effects of a Self-Directed Web-Based Strengthening Exercise and Physical Activity Program for Knee Osteoarthritis." JAMA Intern Med. 2021;181(4):530-538. doi: 10.1001/jamainternalmedicine.2020.8033

52. Sengupta K, et al. "Comparative Efficacy and Tolerability of 5-Loxin and Aflapin Against Osteoarthritis of the Knee." Int J Med Sci. 2010;7(6):366-377. doi: 10.7150/ijms.7.366

53. Murphy RK, et al. "Glucosamine and glaucoma: A potential association." JAMA Ophthalmol. 2013;131(6):753-757. doi: 10.1001/jamaophthalmol.2013.227

54. Esfandiari H, et al. "Effect of glucosamine on intraocular pressure: a randomized clinical trial." Eye (Lond). 2017;31(3):389-394. doi: 10.1038/eye.2016.221

55. Yuenyongviwat V, et al. "Effect of glucosamine sulfate on intraocular pressure." J Fr Ophtalmol. 2019;42(9):e379-e384. doi: 10.1016/j.jfo.2019.03.035

56. Cerda C, et al. "Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease." World J Gastroenterol. 2013;19(32):5381-5384. doi: 10.3748/wjg.v19.i32.5381

57. Tallia AF, et al. "Chondroitin sulfate and asthma exacerbation." J Am Board Fam Pract. 2002;15(6):481-484.

58. Sakko AJ, et al. "Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta 1." Cancer Res. 2003;63(18):5755-5760.

59. Brasky TM, et al. "Glucosamine and chondroitin use in relation to prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort." Nutr Cancer. 2011;63(4):573-582. doi: 10.1080/01635581.2011.553020

60. Acebo E, et al. "Allergic contact dermatitis from Boswellia serrata extract in a naturopathic cream." Contact Dermatitis. 2004;51(5-6):297-298. doi: 10.1111/j.0105-1873.2004.0459j.x

61. Wu KK, et al. "Aspirin and salicylate: an old drug remedy with a new twist." Circulation. 2000;102(17):2022-2023.

62. Chrubasik S, et al. "Treatment of low back pain exacerbations with willow bark extract." Rheumatology (Oxford). 2001;40(12):1388-1393. doi: 10.1093/rheumatology/40.12.1388

63. Boullata JI, et al. "Natural health product interactions with medication." Ann Pharmacother. 2003;37(9):1287-1296. doi: 10.1345/aph.1C371

64. Narat B, et al. "Anaphylaxis to white willow bark." N Am J Med Sci. 2013;5(5):332-333.

65. Navarro SL, et al. "Modulation of gut microbiota by glucosamine and chondroitin: a randomized, double-blind pilot study." Microorganisms. 2019;7(12):610. doi: 10.3390/microorganisms7120610

66. Roy S, et al. "Regulation of vascular responses to inflammation: inducible matrix metalloproteinase-3 expression in human microvascular endothelial cells is sensitive to antiinflammatory Boswellia." Antioxid Redox Signal. 2006;8(5-6):653-660. doi: 10.1089/ars.2006.8.653

67. Gupta I, et al. "Effects of Boswellia serrata gum resin in patients with ulcerative colitis." Eur J Med Res. 1997;2(1):37-43.

68. Gupta I, et al. "Effects of gum resin of Boswellia serrata in patients with chronic colitis." Planta Med. 2001;67(5):391-395. doi: 10.1055/s-2001-15802

69. Dysart SH, et al. "Prescribing patterns for viscosupplementation among US adults with newly diagnosed knee osteoarthritis." Am Health Drug Benefits. 2021;14(3):105-111.